FDA Clears Roche and Eli Lilly Alzheimer's Blood Test

FDA Clearance and Test Functionality

The U.S. Food and Drug Administration (FDA) has cleared a blood test developed by Swiss healthcare group Roche and its partner Eli Lilly to assist in identifying signs of Alzheimer's disease. The test is specifically intended for use in individuals aged 55 and older who are experiencing cognitive decline.

Known as Elecsys pTau217, the product is a biomarker blood test. According to Roche, the test allows physicians to identify patients who are likely or unlikely to have brain changes associated with Alzheimer's disease. However, Roche stated that Elecsys pTau217 is not intended for use as a standalone diagnostic test, and clinicians should interpret the results alongside other clinical information.

Infrastructure and Availability

The test is designed for broad accessibility through existing medical infrastructure. Roche noted that the test can be performed on more than 4,500 Roche laboratory analyzers that are already installed across the United States.

Major laboratory networks have already indicated plans to integrate the test into their services. Quest Diagnostics and Labcorp have both announced intentions to make the test available to patients through their respective lab networks. Quest Diagnostics will add the test to its existing AD-Detect menu of blood-based Alzheimer's biomarker tests. Roche has not disclosed the price of the test.

Regulatory Context and Industry Landscape

The U.S. regulatory clearance follows a similar approval in Europe, which was granted in May. This development occurs as diagnostic companies and drugmakers seek to create simpler testing methods for Alzheimer's to meet an increasing demand for earlier diagnosis and treatment.

Elecsys pTau217 is not the first of its kind to receive such authorization. Fujirebio's Lumipulse became the first blood-based test to receive FDA clearance for the assessment of Alzheimer's disease in 2025.